As of January 31, 2026, licensing agreements for generic versions of the blockbuster drug Revlimid will no longer be volume-limited. This exposes a major revenue source to full generic competition and significant, rapid erosion.
Filing excerpt
For Revlimid, in the U.S., certain generic companies have begun marketing generic lenalidomide products pursuant to volume-limited licenses granted as part of litigation settlements. As of January 31, 2026, the licenses are no longer volume-limited.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kcompetitorNamedGet every 10-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/0e6db75a-4664-4824-b33a-d541f3203eac returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "0e6db75a-4664-4824-b33a-d541f3203eac",
"signal_type": "sec-10k",
"signal_subtype": "competitorNamed",
"detected_at": "2026-02-17T06:30:02.078+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "As of January 31, 2026, licensing agreements for generic versions of the blockbuster drug Revlimid will no longer be volume-limited. This exposes a major revenue source to full generic competition and significant, rapid erosion.",
"metrics": {
"timeframe": "next_year"
},
"summary": "Revlimid loses volume-limited protection against generics on January 31, 2026.",
"excerpts": "For Revlimid, in the U.S., certain generic companies have begun marketing generic lenalidomide products pursuant to volume-limited licenses granted as part of litigation settlements. As of January 31, 2026, the licenses are no longer volume-limited.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Competitive intelligence",
"signal_category": "market",
"regions_mentioned": [
"U.S."
]
}
}
curl https://signals.autobound.ai/v1/signals/0e6db75a-4664-4824-b33a-d541f3203eac \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.